

What is claimed is:

1. A pharmaceutical composition having therapeutic synergy comprising:
5 20(S)-camptothecin, an analog of 20(S)-camptothecin, or a derivative of 20(S)-camptothecin; and
 at least one of an alkylating agent, epidophyllotoxin, antimetabolite, antibiotic or vinca alkaloid.
- 10 2. A pharmaceutical composition according to claim 1, wherein the alkylating agent is cyclophosphamide, ifosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine.
- 15 3. A pharmaceutical composition according to claim 1, wherein the antimetabolite is 5-fluorouracil, cytarabine or a folic acid analog.
4. A pharmaceutical composition according to claim 1, wherein the antibiotic is daunorubicine, doxorubicin, bleomycin or mitomycin.
- 20 5. A pharmaceutical composition according to claim 1, wherein the vinca alkaloid is vinblastine, vincristine, or their synthetic analogues.
6. A pharmaceutical composition according to claim 1, wherein the epidophyllotoxin is etoposide or teniposide.
- 25 7. A pharmaceutical composition according to claim 1, wherein said composition is useful in the treatment of neoplastic diseases.
8. A pharmaceutical composition according to claim 1, wherein the
30 20(S)-camptothecin is 9-amino-20(S)-camptothecin.

9. A pharmaceutical composition according to claim 1, wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.

5 10. A method for treating disease comprising:
delivering to a patient in need of treatment a therapeutically effective amount of 20(S)-camptothecin, an analog of 20(S)-camptothecin, or a derivative of 20(S)-camptothecin in combination with an effective amount of at least one of an alkylating agent, epidophyllotoxin, antimetabolite, antibiotic or vinca alkaloid.

10 11. A method according to claim 10, wherein the alkylating agent is cyclophosphamide, ifosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine.

15 12. A method according to claim 10, wherein the antimetabolite is 5-fluorouracil, cytarabine or a folic acid analog.

20 13. A method according to claim 10, wherein the antibiotic is daunorubicine, doxorubicin, bleomycin or mitomycin.

25 14. A method according to claim 10, wherein the vinca alkaloid is vinblastine, vincristine, or their synthetic analogues.

15. A method according to claim 10, wherein the epidophyllotoxin is etoposide or teniposide.

16. A method according to claim 10, wherein said composition is useful in the treatment of neoplastic diseases.

17. A method according to claim 10, wherein the 20(S)-camptothecin is 9-amino-20(S)-camptothecin.

18. A method according to claim 10, wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.

5

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

COMBINATION THERAPY INCLUDING CAMPTOTHECIN

Inventor: Joseph Rubinfeld

5 A method for treating diseases comprises delivering to a patient
in need of treatment a therapeutically effective amount of 20(S)-
camptothecin, an analog of 20(S)-camptothecin, or a derivative of
20(S)-camptothecin in combination with an effective amount of at least
10 one of an alkylating agent, epidophyllotoxin, antimetabolite, antibiotic
or vinca alkaloid.